Regulatory Filing
Granules India Secures Sole First-to-File ANDA Status for Sodium Oxybate Extended-Release Oral Suspension
NSE
granules
BSE
532482
Granules India Limited has secured Sole First-to-File (FTF) status for its Abbreviated New Drug Application (ANDA) for Sodium Oxybate Extended-Release for Oral Suspension, the generic equivalent of LUMRYZ® extended-release oral suspension. This marks the company’s second Sole First-to-File ANDA and strengthens its complex generics pipeline and regulatory position in the U.S. pharmaceutical market.
PRICE-SENSITIVE TRIGGER
Event: Granules India receives Sole First-to-File ANDA status.
Type: Regulatory Filing
Impact: Positive
Immediate Effect: The Sole First-to-File designation enhances Granules India’s competitive positioning in the U.S. generics market and reinforces its capabilities in developing differentiated complex generic products.
Key Metrics:
Segment Performance:
- Strengthening of the Complex Generics business.
- Expansion of the U.S. regulated market portfolio.
- Continued investment in R&D and regulatory capabilities.
Highlight:
- Granules India has secured its second Sole First-to-File ANDA, providing an important strategic milestone in its complex generics business and potentially strengthening its future U.S. product pipeline.
What Happened ?
Granules India Limited announced that it has received Sole First-to-File (FTF) status for its Abbreviated New Drug Application (ANDA) covering Sodium Oxybate Extended-Release for Oral Suspension, the generic version of LUMRYZ® extended-release oral suspension.
The achievement represents the company’s second Sole First-to-File ANDA, following its earlier success with Amphetamine Extended-Release Tablets, the generic equivalent of Dyanavel XR®.
According to the company, the latest regulatory milestone further demonstrates its growing expertise in developing differentiated and technically complex generic pharmaceutical products for regulated markets, particularly the United States.
Key Details
Regulatory Milestone:
- Secured Sole First-to-File status for Sodium Oxybate Extended-Release for Oral Suspension ANDA.
- Product is the generic equivalent of LUMRYZ®.
- Marks Granules India’s second Sole First-to-File ANDA.
Strategic Importance:
- Reinforces the company’s focus on complex generic formulations.
- Strengthens its competitive position within the U.S. pharmaceutical market.
- Demonstrates continued advancement in R&D and regulatory execution.
- Supports long-term portfolio expansion into differentiated products.
Product Overview:
- Sodium Oxybate Extended-Release Oral Suspension is indicated in the United States for the treatment of:
- Cataplexy associated with narcolepsy.
- Excessive daytime sleepiness in patients with narcolepsy.
Business Implications:
- Expands Granules India’s intellectual and regulatory positioning in complex generics.
- Enhances opportunities within the high-value U.S. specialty generics market.
- Supports the company’s strategy of developing differentiated products rather than competing solely in commoditized generic categories.
Risk Analysis
Summary:
- The announcement confirms a regulatory milestone but does not disclose commercial launch timelines, exclusivity economics, expected revenues, or financial contribution. Commercial benefits remain subject to regulatory approvals, market dynamics, and execution.
Key Risks:
- Final regulatory approvals remain necessary before commercialization.
- Commercial launch timing has not been disclosed.
- Market opportunity depends on competitive landscape and patent-related developments.
- Financial impact has not yet been quantified.
Worst Case:
- Delays in commercialization or increased competition could postpone or reduce the economic benefits associated with the First-to-File opportunity.
Risk Level: Medium
Company Commentary
- Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, stated that securing Sole First-to-File status for the Sodium Oxybate Extended-Release Oral Suspension ANDA is another important milestone in the company’s complex generics journey.
- He noted that the achievement reflects the strength of Granules India’s R&D and regulatory capabilities while reinforcing its commitment to building a differentiated product portfolio, expanding patient access to affordable treatment options, and delivering sustainable long-term growth.
Official Exchange Filing: Granules India Limited
